Return on Invested Capital (ROIC): 13.62%
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 13.62% is 23% below its 5-year average of 17.70%, near the low end of its 5-year range (13.62%–23.54%).
As of Saturday, June 27, 2026. 7.06% below its 12-month average of 14.65%.
WST Return on Invested Capital (ROIC) Chart
Annual fiscal-year return on invested capital; no daily interpolation.
WST Average Return on Invested Capital (ROIC) Chart
WST Current vs Average Return on Invested Capital (ROIC) Chart
WST Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
13.62%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
14.65%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
16.90%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
17.70%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
14.31%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
12.31%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
11.04%
CURRENT VS TTM AVG
-7.06%
CURRENT VS 3Y AVG
-19.42%
CURRENT VS 5Y AVG
-23.04%
CURRENT VS 10Y AVG
-4.81%
CURRENT VS 15Y AVG
+10.61%
CURRENT VS 20Y AVG
+23.42%
WST Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.79B | 13.62% | 14.65% | 16.90% | 17.70% |
| Waters Corporation (WAT)vs › | $24.41B | 17.57% | 18.00% | 20.73% | 22.79% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.54B | 35.46% | 38.26% | 37.51% | 36.01% |
| Quest Diagnostics Incorporated (DGX)vs › | $23.23B | 8.43% | 7.70% | 8.24% | 10.04% |
| BioNTech SE (BNTX)vs › | $23.07B | -3.14% | -4.79% | 9.55% | 20.42% |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 16.14% | 15.79% | 14.57% | 13.09% |
| Moderna, Inc. (MRNA)vs › | $26.69B | -29.70% | -31.12% | -12.69% | 0.19% |
| Incyte Corporation (INCY)vs › | $22.73B | 20.58% | 10.42% | 9.36% | 7.13% |
| DexCom, Inc. (DXCM)vs › | $27.07B | 16.61% | 13.40% | 11.07% | 9.62% |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 7.39% | 6.30% | 5.64% | 7.56% |
Capital Efficiency
ROIC
13.6%
ROE
18.1%
Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for West Pharmaceutical Services, Inc. (WST)?
- The return on invested capital (ROIC) for WST stock is 13.62%.
- Is West Pharmaceutical Services, Inc.'s return on invested capital (ROIC) high or low?
- The return on invested capital (ROIC) of 13.62% is 23% below its 5-year average of 17.70%, near the low end of its 5-year range (13.62%–23.54%).
- What is the TTM average return on invested capital (ROIC) for West Pharmaceutical Services, Inc. (WST)?
- The TTM average return on invested capital (ROIC) for WST stock is 14.65%.
- What is the 3Y average return on invested capital (ROIC) for West Pharmaceutical Services, Inc. (WST)?
- The 3Y average return on invested capital (ROIC) for WST stock is 16.90%.
- What is the 5Y average return on invested capital (ROIC) for West Pharmaceutical Services, Inc. (WST)?
- The 5Y average return on invested capital (ROIC) for WST stock is 17.70%.
- What is the 10Y average return on invested capital (ROIC) for West Pharmaceutical Services, Inc. (WST)?
- The 10Y average return on invested capital (ROIC) for WST stock is 14.31%.
- What is the 15Y average return on invested capital (ROIC) for West Pharmaceutical Services, Inc. (WST)?
- The 15Y average return on invested capital (ROIC) for WST stock is 12.31%.
- What is the 20Y average return on invested capital (ROIC) for West Pharmaceutical Services, Inc. (WST)?
- The 20Y average return on invested capital (ROIC) for WST stock is 11.04%.
WST Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 13.62% |
| 2024-12-31 | 15.69% |
| 2023-12-31 | 17.81% |
| 2022-12-31 | 20.49% |
| 2021-12-31 | 23.54% |
| 2020-12-31 | 15.04% |
| 2019-12-31 | 11.87% |
| 2018-12-31 | 12.52% |
| 2017-12-31 | 9.44% |
| 2016-12-31 | 10.57% |
| 2015-12-31 | 6.80% |
| 2014-12-31 | 9.18% |
| 2013-12-31 | 8.03% |
| 2012-12-31 | 7.28% |
| 2011-12-31 | 7.33% |
| 2010-12-31 | 7.80% |
| 2009-12-31 | 8.12% |
| 2008-12-31 | 9.65% |
| 2007-12-31 | 9.08% |
| 2006-12-31 | 9.92% |
| 2005-12-31 | 10.47% |
| 2004-12-31 | 8.45% |
| 2003-12-31 | 6.85% |
| 2002-12-31 | 4.37% |
| 2001-12-31 | 6.41% |
| 2000-12-31 | 3.83% |
| 1999-12-31 | 9.43% |
| 1998-12-31 | 3.55% |
| 1997-12-31 | 11.30% |
| 1996-12-31 | 7.75% |
Related Metrics
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green